We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+9.04%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$661M
AUM Growth
+$34.1M
Cap. Flow
-$6.85M
Cap. Flow %
-1.04%
Top 10 Hldgs %
25.72%
Holding
101
New
10
Increased
24
Reduced
44
Closed
5

Top Buys

Rank Stock Value
1
PRGO icon
Perrigo
PRGO
+$12.3M
2
ABMD
Abiomed Inc
ABMD
+$12.2M
3
WBA
Walgreens Boots Alliance
WBA
+$11.2M
4
CVS icon
CVS Health
CVS
+$8.13M
5
BHC icon
Bausch Health
BHC
+$7.75M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$8.33M
2
ALKS icon
Alkermes
ALKS
+$6.79M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$5.92M
4
HCA icon
HCA Healthcare
HCA
+$5.86M
5
EW icon
Edwards Lifesciences
EW
+$5.84M

Sector Composition

Rank Sector Weight
1 Healthcare 92.69%
2 Financials 1.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COO icon
51
Cooper Companies
COO
$14.5B
$4.96M 0.75%
148,000
+16,000
+12% +$573K
CERN
52
DELISTED
Cerner Corp
CERN
$4.93M 0.75%
82,000
-34,000
-29% -$2.09M
COR icon
53
Cencora
COR
$61.2B
$4.77M 0.72%
46,000
-17,000
-27% -$1.67M
IOVA icon
54
Iovance Biotherapeutics
IOVA
$2.87B
$4.44M 0.67%
575,000
-108,108
-16% -$750K
ACAD icon
55
Acadia Pharmaceuticals
ACAD
$5.03B
$4.28M 0.65%
120,000
-76,000
-39% -$2.68M
ELGX
56
DELISTED
Endologix Inc
ELGX
$4.16M 0.63%
42,000
+19,100
+83% +$2.05M
IONS icon
57
Ionis Pharmaceuticals
IONS
$9.4B
$4.15M 0.63%
67,000
-13,000
-16% -$701K
LIVN icon
58
LivaNova
LIVN
$4.2B
$3.92M 0.59%
+66,000
New +$4.01M
ICPT
59
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$3.88M 0.59%
26,000
-6,000
-19% -$1.02M
SUPN icon
60
Supernus Pharmaceuticals
SUPN
$2.77B
$3.87M 0.59%
288,000
-65,328
-18% -$1.01M
EW icon
61
Edwards Lifesciences
EW
$51.7B
$3.87M 0.59%
147,000
-225,000
-60% -$5.84M
ZLTQ
62
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$3.65M 0.55%
128,000
-29,000
-18% -$916K
PODD icon
63
Insulet
PODD
$9.79B
$3.63M 0.55%
96,000
-14,000
-13% -$471K
BXLT
64
DELISTED
BAXALTA INC COM STK (DE)
BXLT
$3.44M 0.52%
+88,000
New +$3.07M
HTWR
65
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$3.38M 0.51%
67,000
-20,000
-23% -$940K
PTLA
66
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$3.19M 0.48%
62,000
-9,000
-13% -$436K
HZNP
67
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$3.16M 0.48%
+146,000
New +$2.84M
MGNX icon
68
MacroGenics
MGNX
$257M
$2.91M 0.44%
94,000
-13,959
-13% -$424K
ACHN
69
DELISTED
Achillion Pharmaceuticals
ACHN
$2.87M 0.43%
266,000
-14,000
-5% -$127K
CPHD
70
DELISTED
Cepheid Inc
CPHD
$2.74M 0.41%
75,000
+24,000
+47% +$853K
PCRX icon
71
Pacira BioSciences
PCRX
$997M
$2.69M 0.41%
+35,000
New +$1.98M
ARIA
72
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$2.69M 0.41%
430,000
– –
TSRO
73
DELISTED
TESARO, Inc.
TSRO
$2.66M 0.4%
50,899
– –
XNCR icon
74
Xencor
XNCR
$1.55B
$2.65M 0.4%
181,303
– –
EXEL icon
75
Exelixis
EXEL
$13.4B
$2.59M 0.39%
+460,000
New +$2.57M
1 2
3
4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2015 Portfolio in Review

As of Q4 2015, Rhenman & Partners Asset Management held 101 positions worth $661M, up 5.4% from $627M the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Rhenman & Partners Asset Management's Q4 2015 filing shows 10 new, 24 increased, 44 reduced and 5 closed positions. Its largest new stake was Walgreens Boots Alliance: 132,000 shares worth $11.2M. The largest sale was Amgen, an estimated $8.33M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Financials.

  • Rhenman & Partners Asset Management's largest Q4 2015 buy was Walgreens Boots Alliance: 132,000 shares worth $11.2M.
  • Rhenman & Partners Asset Management added most to Perrigo in Q4 2015, an estimated $12.3M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2015 reduction was Amgen, cutting an estimated $8.33M.
  • Rhenman & Partners Asset Management fully exited Merck in Q4 2015, selling an estimated $4.94M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 26% of its $661M portfolio in Q4 2015.
  • Rhenman & Partners Asset Management opened 10 new positions and closed 5 in Q4 2015.
  • Rhenman & Partners Asset Management's portfolio value rose 5.4% quarter-over-quarter to $661M.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2015, filed 19 Jan 2016.